ReviewInternational journal of oncology2015
Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review).
Review in International journal of oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical significance of miRNA‑1 and its potential target gene network in lung squamous cell carcinoma.Molecular medicine reports · 2019Pooled it
- Urine miRNA signature as potential non-invasive diagnostic biomarker for Hirschsprung's disease.Frontiers in molecular neuroscience · 2024Article
- Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy.Translational oncology · 2021Review
- MiR-374b-5p inhibits KDM5B-induced epithelial-mesenchymal transition in pancreatic cancer.American journal of cancer research · 2021Article
- miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer.Frontiers in oncology · 2021Article
- Impact of mirna-21 on survival prognosis in patients with pancreatic cancer: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Serum miR-1290 and miR-1246 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.Journal of Cancer · 2020Article
- Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer.Theranostics · 2020Article
- miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer.Frontiers in immunology · 2020Article
- The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation.Frontiers in bioengineering and biotechnology · 2020Article
- Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.Small GTPases · 2019Article
- P21 activated kinase 2 promotes pancreatic cancer growth and metastasis.Oncology letters · 2019Article
- MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.Seminars in cancer biology · 2019Review
- The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery.Journal of oncology · 2019Article
- Restoration of miRNA-148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β-catenin signaling pathway via downregulating maternally expressed gene-3.Experimental and therapeutic medicine · 2019Article
- MicroRNA-769-5p Inhibits Pancreatic Ductal Adenocarcinoma Progression by Directly Targeting and Downregulating ETS Proto-Oncogene 1.OncoTargets and therapy · 2019Article
- miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression.Molecular medicine reports · 2018Article
- MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protein kinase 1.Oncology letters · 2018Article
- Review
- MicroRNAs in pancreatic cancer diagnosis and therapy.Central-European journal of immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the leading causes of cancer related death. Increasing incidence and mortality indicates a lack of detection and post diagnostic management of this disease. Recent evidences suggest that, miRNAs are very attractive target molecules that can serve as biomarkers for predicting development and progression of pancreatic cancer. Furthermore, miRNAs are also promising therapeutic targets for pancreatic cancer. The objective of the present review is to discuss the significance of miRNA in pancreatic cancer development, diagnosis, therapy and prognosis. We extracted and compiled the useful information from PubMed database, which satisfied our criteria for analysis of miRNAs in pancreatic cancer diagnosis, therapy and prognosis. A summary of the most important miRNAs known to regulate pancreatic tumorigenesis is provided. The review also provides a collection of evidence that show miRNA profiles of biofluids hold much promise for use as biomarkers to predict and detect development of pancreatic cancer in its early stages. Identification of key miRNA networks in pancreatic cancer will provide long-awaited diagnostic/therapeutic/prognostic tools for early detection, better treatment options, and extended life expectancy and quality of life in PDAC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.